October 24, 2022
The Pharmaceuticals and Medical Devices Agency (PMDA) is looking into new side effect risks for a batch of drugs including Astellas Pharma’s HIF-PH inhibitor Evrenzo (roxadustat), a move likely to trigger label changes in the near future. According to the...read more